Targovax reports OS data for TG01 vaccine in pancreatic cancer

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, Targovax A/S (OSE:TRVX) reported data from 19 evaluable patients with surgically resected pancreatic cancer in the open-label, European Phase I/II TG01-01 trial showing that 0.7 mg intradermal TG01 plus GM-CSF and gemcitabine led to a median overall survival (OS) of 33.1 months.

The trial’s primary endpoints are safety and immune response. Secondary endpoints include disease-free survival (DFS), OS and the relationship between K-Ras (KRAS) status and recurrence. Targovax has previously reported data from the trial (see BioCentury, Feb. 17, 2014; July 20, 2015 & March 14, 2016)...